(Reuters) – U.S. drugmaker Eli Lilly and Co plans to sell a half-price version of its Humalog insulin injection, as it fends off criticism about rising drug prices.
Lilly said on Monday the new version would be called Insulin Lispro, while Humalog would remain available for patients who want to continue accessing it through their current insurance plans.
The news comes as the U.S. government intensifies its scrutiny of the pharmaceutical industry and rising U.S. prescription drug prices, a top voter concern and a priority of President Donald Trump’s administration.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, Reuters reported in January.
“We’ve engaged in discussions about the price of insulin with many different stakeholders … people living with diabetes, caregivers, advocacy groups, health care professionals, payers, wholesalers, lawmakers,” Lilly’s Chief Executive Officer David Ricks said in a statement.
The list price of one vial of Insulin Lispro would be $137.35, Lilly said. The list price of a drug is not necessarily what patients actually pay. “Out-of-pocket” costs vary based on the duration of the treatment and individual healthcare plans.
Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar